文献速递血栓与止血

重组血管性血友病因子与氨甲环酸治疗美国轻中度血管性血友病女性月经过多的比较(VWDMin):一项3期、开放标签、随机交叉试验

Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial.
PubMed 文献 · Lancet Haematol · 2023-06-26

VWDMin是一项在美国13个血友病治疗中心开展的3期开放标签随机交叉试验,纳入39例轻中度血管性血友病伴月经过多女性患者,比较重组血管性血友病因子与氨甲环酸两个周期后的PBAC评分。主要终点未达到,氨甲环酸组中位PBAC评分显著低于重组血管性血友病因子组,无严重不良事件或治疗相关死亡。

要点

  • 氨甲环酸两个周期后中位PBAC评分显著低于重组血管性血友病因子(146 vs 213,p=0.039)。
  • 主要终点未达到,两种治疗均未使PBAC评分恢复至正常范围。
  • 无严重不良事件、治疗相关死亡或3-4级不良事件。

核心结论

  • 这些中期数据提示,在减少轻中度血管性血友病患者月经过多方面,重组血管性血友病因子不优于氨甲环酸。
  • 这些发现支持基于患者偏好和生活经历与其讨论月经过多的治疗选择。

研究设计与样本

  • VWDMin是一项3期、开放标签、随机交叉试验,在美国13个血友病治疗中心开展。
  • 纳入13-45岁、血管性血友病因子瑞斯托霉素辅因子小于0.50 IU/mL的轻中度血管性血友病女性患者,且过去两个周期中至少一个周期PBAC评分大于100。
  • 参与者按1:1随机分配至两个连续周期的静脉重组血管性血友病因子40 IU/kg(第1天5-10分钟内输注)和口服氨甲环酸1300 mg每日三次(第1-5天),顺序由随机化决定。
  • 主要结局为两个周期治疗后第5天PBAC评分降低40分。
  • 试验因招募缓慢于2022年2月15日经数据安全监测委员会要求提前终止,注册号ClinicalTrials.gov NCT02606045。

主要发现

  • 2019年2月12日至2021年11月16日共纳入39例患者,36例完成试验(17例先接受重组血管性血友病因子后氨甲环酸,19例先接受氨甲环酸后重组血管性血友病因子)。
  • 此次非计划中期分析(数据截止2022年1月27日)中位随访23.97周(IQR 21.81-28.14)。
  • 主要终点未达到,两种治疗均未使PBAC评分恢复至正常范围。
  • 氨甲环酸两个周期后中位PBAC评分显著低于重组血管性血友病因子(146 [95% CI 117-199] vs 213 [152-298];校正平均治疗差异46 [95% CI 2-90];p=0.039)。
  • 无严重不良事件或治疗相关死亡,无3-4级不良事件;最常见的1-2级不良事件为黏膜出血(氨甲环酸治疗期间4例[6%] vs 重组血管性血友病因子治疗期间0例)和其他出血(4例[6%] vs 2例[3%])。

临床怎么用

  • 作者认为,这些中期数据提示重组血管性血友病因子不优于氨甲环酸。
  • 作者建议基于患者偏好和生活经历与其讨论月经过多的治疗选择。

局限性

  • 试验因招募缓慢提前终止。
  • 此次分析为非计划中期分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heavy menstrual bleeding occurs in 80% of women with von Willebrand disease and is associated with iron deficiency and poor response to current therapies. International guidelines indicate low certainty regarding effectiveness of hormonal therapy and tranexamic acid. Although von Willebrand factor (VWF) concentrate is approved for bleeds, no prospective trials guide its use in heavy menstrual bleeding. We aimed to compare recombinant VWF with tranexamic acid for reducing heavy menstrual bleeding in patients with von Willebrand disease. METHODS: VWDMin, a phase 3, open-label, randomised crossover trial, was done in 13 haemophilia treatment centres in the USA. Female patients aged 13-45 years with mild or moderate von Willebrand disease, defined as VWF ristocetin cofactor less than 0·50 IU/mL, and heavy menstrual bleeding, defined as a pictorial blood assessment chart (PBAC) score more than 100 in one of the past two cycles were eligible for enrolment. Participants were randomly assigned (1:1) to two consecutive cycles each of intravenous recombinant VWF, 40 IU/kg over 5-10 min on day 1, and oral tranexamic acid 1300 mg three times daily on days 1-5, the order determined by randomisation. The primary outcome was a 40-point reduction in PBAC score by day 5 after two cycles of treatment. Efficacy and safety were analysed in all patients with any post-baseline PBAC scores. The trial was stopped early due to slow recruitment on Feb 15, 2022, by a data safety monitoring board request, and was registered at ClinicalTrials.gov, NCT02606045. FINDINGS: Between Feb 12, 2019, and Nov 16, 2021, 39 patients were enrolled, 36 of whom completed the trial (17 received recombinant VWF then tranexamic acid and 19 received tranexamic acid then recombinant VWF). At the time of this unplanned interim analysis (data cutoff Jan 27, 2022), median follow-up was 23·97 weeks (IQR 21·81-28·14). The primary endpoint was not met, neither treatment corrected PBAC score to the normal range. Median PBAC score was significantly lower after two cycles with tranexamic acid than with recombinant VWF (146 [95% CI 117-199] vs 213 [152-298]; adjusted mean treatment difference 46 [95% CI 2-90]; p=0·039). There were no serious adverse events or treatment-related deaths and no grade 3-4 adverse events. The most common grade 1-2 adverse events were mucosal bleeding (four [6%] patients during tranexamic acid treatment vs zero during recombinant VWF treatment) and other bleeding (four [6%] vs two [3%]). INTERPRETATION: These interim data suggest that recombinant VWF is not superior to tranexamic acid in reducing heavy menstrual bleeding in patients with mild or moderate von Willebrand disease. These findings support discussion of treatment options for heavy menstrual bleeding with patients based on their preferences and lived experience. FUNDING: National Heart Lung Blood Institute (National Institutes of Health).

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Ragni MV, Rothenberger SD, Feldman R, et al. Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial. Lancet Haematol. 2023. PMID: 37385272. doi:10.1016/S2352-3026(23)00119-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。